ESMO 2023 Update – ALINA: Adjuvant Alectinib Improves Disease-Free Survival in Resected Early-Stage Non-Small Cell Lung Cancer Author: Lei Deng,…
ESMO 2023 Update – CheckMate 77T: Another Phase 3 Trial of Perioperative Immunotherapy Improving Event-Free Survival for Resectable Stage II-III…
Presented by: Chris Chen, MD, Director, Early Drug Development, Stanford Cancer Institute Covered by: Inas Abuali, MD, FACP Dr. Chris…
By Akshat Jain MD, MPH Hematology Oncology and Cellular Therapy Faculty Department of Pediatrics & Clinical Medicine Loma Linda University…
X-7/7 trial: Alternative fixed dosing of capecitabine associated with similar efficacy with better safety profile By Drs. Arya Mariam…
By Dr. Aakash Desai Mayo Clinic KEYNOTE-789: No Significant Efficacy Benefit with Addition of Pembrolizumab to Chemotherapy in TKI-Resistant,…
By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center Hodgkin’s lymphoma (HL) has had an exciting and…
Imetelstat in low-risk MDS for transfusion independence By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center …
By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center Low-risk MDS had many exciting updates, starting with…
Author: Lei Deng, MD Roswell Park Comprehensive Cancer Center Live report from ASCO23, Chicago, IL June 6, 2023 …